Drugs that contain Casimersen
1. Drug name - AMONDYS 45
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US8524880 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Apr, 2026
(3 years from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(8 years from now) | |
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(8 years from now) | |
| CN103003430A | SAREPTA THERAPS INC | Antisense Molecule And Method For Treating Disease. |
Oct, 2016
(5 years ago) | |
| CN105838714A | SAREPTA THERAPS INC | Antisense Molecule And Method For Treating Disease. |
Nov, 2030
(8 years from now) | |
| CN105838714B | SAREPTA THERAPS INC | Antisense Molecules And Method For Treating Disease |
Nov, 2030
(8 years from now) | |
| IN347912B | SAREPTA THERAPS INC | Antisense Molecules And Methods For Treating Pathologies |
Nov, 2030
(8 years from now) | |
| IN201204202P4 | SAREPTA THERAPS INC | Antisense Molecules And Methods For Treating Pathologies |
Nov, 2030
(8 years from now) | |
| EP2206781A9 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP2206781A2 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP2206781A3 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP2206781B1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP1766010A1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP1766010B1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2500430B1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2500430A2 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP1766010A4 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2500430A3 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2499249A1 | SAREPTA THERAPS INC | Antisense Molecules And Methods For Treating Pathologies |
Nov, 2030
(8 years from now) | |
| EP2499249A4 | SAREPTA THERAPS INC | Antisense Molecules And Methods For Treating Pathologies |
Nov, 2030
(8 years from now) | |
| EP2499249B1 | SAREPTA THERAPS INC | Antisense Molecules And Methods For Treating Pathologies |
Nov, 2030
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(8 years from now) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(8 years from now) | |
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/2ML (50MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.